CB-012
Acute Myeloid Leukemia (AML)
Key Facts
About Caribou Biosciences
Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is a clinical-stage biotech focused on developing allogeneic CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company's mission is to create readily available, 'off-the-shelf' cell therapies that address the manufacturing complexities, high costs, and delays associated with personalized autologous treatments. Its strategy centers on 'armoring' these therapies through multiplex gene editing to enhance persistence and activity, with multiple Phase 1 clinical trials underway for B-cell non-Hodgkin lymphoma and multiple myeloma. Caribou aims to translate its foundational CRISPR science into transformative medicines for hematologic cancers.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |